Table 1 Patient Demographics and Baseline Characteristics.
From: CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation
All Patients (n = 87) | Patients with AF (n= 37) | Patients without AF (n = 50) | |
|---|---|---|---|
Age (years) | 58 ± 13 | 59 ± 15 | 56 ± 11 |
Male gender | 54 (61%) | 22 (59%) | 32 (64%) |
Hypertension | 8 (9%) | 3(8%) | 5(10%) |
Diabetes mellitus | 6 (7%) | 3(8%) | 3(6%) |
NYHA functional class | |||
I | 41 (47%) | 17(46%) | 24(48%) |
II | 38 (44%) | 16(43%) | 22(44%) |
III/IV | 8 (9%) | 4(10%) | 4(8%) |
Family history of HCM or sudden death | 20 (23%) | 9(24%) | 11(22%) |
Syncope | 6 (7%) | 4(10%) | 2(4%) |
Atrial fibrillation | 37 (43%) | ||
None | 50(57%) | 0 | 50(100%) |
Paroxysmal | 27(31%) | 27 (73%) | 0 |
Persistent | 10(12%) | 10 (27%) | 0 |
Echocardiographic data | |||
LV diastolic dysfunction, n (%) | 35 (40%) | 22 (59%) | 13 (26%) |
Mitral regurgitation | |||
1 | 27 (31%) | 15 (40%) | 12 (24%) |
≥ 2 | 12(14%) | 7 (18%) | 5 (10%) |
Medications, n (%) | |||
Beta-blocker | 45(52%) | 20 (55%) | 25 (49%) |
Calcium-channel blocker | 16(18%) | 7 (18%) | 9 (18%) |
Amiodarone | 9(10%) | 5(13%) | 4 (8%) |